Sulistyo M. Agustini: Department of Clinical Pathology Medicine Faculty of Muhammadiyah Malang University 2011

MYELODYSPLASTIC SYNDROME
(MYELODYSPLASIA=MDS)
& Multiple myeloma (MM)
Sulistyo M. Agustini
Department of Clinical Pathology
Medicine Faculty of Muhammadiyah Malang University
2011
REFERENCE
• McCance Huether, PATHOPHYSIOLOGY “The
Biologic Basic for Disease in Adults and Children,
Fifth edition, Mosby-Elsevier, 2006
• Hoffbrand AV, Pettit JE and Moss PAH, Essential
HAEMATOLOGY, fourth edition, 2003
• Howard MR, Hamilton PJ, HAEMATOLOGY An
Illustrated Colour Text, tjird edition, 2008
• Kumar Hagler Schneider, Robin and Cotran
PATHOLOGIC BASIC of DISEASE, 7 th edition,
2005
• Abeloff D et al, CLINICAL ONCOLOGY, 3 rd
edition, 2004
INTRODUCTION
• Group of clonal disorder of multipotent
haematopoiesis stem cell (neoplastic disorder)
• MDS is heterogenous group of clonal disorders of
bone marrow, differentiates ineffectivelly
• Their common feature is bone marrow failure
ineffective haematopoiesis (reduced
haematopoiesis activity)
• Hypercellular marrow & peripheral blood cytopenia
• Predominantly a disease of the elderly
• Prognosis is highly variable dependent on the
subtype
Characteristic
• Increasing bone marrow failure
quantitative & qualitative abnormal all
three myeloid cell line
• Ineffective haematopoiesis (reduced
haematopoiesis activity)
• Dysplastic morphological abnormalities
form the basic for diagnosis
• Increased apoptosis within the marrow is
comman feature
First Previous Next Last Index Text

Slide 3 of 50
Myelodysplastic Syndromes
• Clonal disorders involving bone marrow
stem cells that lead to ineffective and
disorderly hematopoiesis
• Manifest as irreversible quantitative and
qualitative defects of hematopoietic cells
cause by abnormal division, maturation
and production of erythrocytes,
granulocytes/monocytes and platelet that
result in blood cytopenias.
Classification
The French American British (FAB) & WHO
type Pheripheral blood Bone marrow Approximated
survival (months)
Refractory anaemia Blast < 1% Blast < 5 % 50

(RA)
RA with ring Blast <1 % Blast <5 % ring 50

sideroblasts (RARS) sideroblast > 15 %
of total erytroblast
RA with excess blasts Blast < 5 % Blast 5 – 20 % 11

(RAEB)
RAEB in transformation Blast > 5 % Blast 20-30 % or 5

(RAEB-t) Auer rods present
Chronic As any of the above As any of the above 11

myelomonocytic 10 x 106/l promonocytes
leukemia (CMML) monocytes
Approach to Diagnosis
Laboratory diagnosis of MDS
• CBC + blood smear exam for dysplastic
• LDH
• BM aspiration (Romanowsky& Iron) and
Biopsy
• BM Cytogenetic
• Flowcytometry (clinically indicated)
• Molecular (clinically indicated)
• Vit B12, Folate , SI-IBC,Feritin (clinically
indicated)
Clinical Aspects
•Most common in elderly ( 60 – 75 ) years
•Few patients < 50 years
•May Affect any age including children
•Men are slightly more than women
Symptoms
Related to blood cytopenias
Clinical Aspects
Symptoms
• Most frequent
– Fatique, weakness and malaise due to
anemia
• Less frequent
– Infection due to the netropenia
– Hemorrhage due to thrombocytopenia.
• Some individual are asymptomatic
– Cytopeniasidentified in routine blood count
• Small percentage (rare)
– Hepato- splenomegaly
Hematologic Finding
• Highly Variable
• Various combination of Cytopenias
– Pancytopenia
– Anemia in combination with neutropenia or
thrombocytopenia
• Ineffective hematopoiesis, dyserythropoiesis,
dysgranulopoiesis and dysmegakaryopoiesis
• Increased myeloblasts
• Normocellular or hypercellular BM
Hematologic Finding
• Most common example
normo or hypercellular BM with
ineffective erythropoiesis , erythroid
hyperplasia
anemia with reticulocytopenia
Dyserythropoiesis
Hematologic Finding
Blood cell Measurements
• Normocytic or macrocytic anemia
low or normal reticulocyte
RDW elevated (anisocytosis)
• Leukocyte normal to markedly reduced
Elevated In minority of cases
• Platelet count reduced or normal
Elevated in special type MDS isolated del (5q)
Hematologic Finding
Bone Marrow Examination
• Hypercellular or Normocellular
Hypocellular (very rare)
• Dysplastic changes
Dyserythropoiesis,
Dysgranulopoiesis,
Dysmegakaryopoiesis
• Increased Myeloblast (< 20%)
• Iron stores often increased (RARS)
Dyserythropoiesis
RARS
Dysgranulopoiesis
PelgerHuet
RAEB
RAEB
Dysmegakaryopoiesis
Prognostic Factors in MDS
• Clinical
– Therapy related MDS
• Blood
– Severe cytopenias
– Raised LDH & Beta 2 microglobulin
• Marrow
– Increased Blast
– Trilineage Dysplasia
• Chromosome abnormalities
– Loss of chromosome 5 or 7
– Deletion of chromosome 3q,5q (excluding 5q
syndrome),7q,17 p
– Structural abnormality of chromosome 11q 23
Prognostic Factor in MDS
• Chromosome abnormalities
– Complex chromosome abnormalities
– Karyotypic evolution
• Genetic/epigenetic abnormalities
– p53, RAS mutation
– Overexpression of WT1
– P15 hypermethylation
– Telomere shortening
– Gene expression profile
• Immunophenotyping
– CD7 positive Blast
Diagnosis MDS
• At least cytopenia of one line
• Morphologic evidence of dysplasia
• Peripheral blood smear, bone marrow
aspirate and biopsy required
• BM differential count performing 500 cells,
eliminating lymphocyte and plasma cells for
the count
• If erythroid precursors > 50 %  NEC Blast
International Prognostic Scoring
System
International Prognostic Scoring
System
• Patients with 20-30 % blasts may be considered
as MDS or AML.
• Cytogenetics:
– Good = normal, -Y alone, del(5q) alone, del(20q)
alone;
– Poor = complex ( 3 abnormalities) or chromosome 7
anomalies;
– Intermediate = other abnormalities. [This excludes
karyotypes t(8;21), inv16, and t(15;17), which are
considered to be AML not MDS.] ³
• Cytopenias:
– neutrophil count <1,800/mcL, platelets <
100,000/mcL, Hb< 10g/dL.
Summary
• MDS is a heterogeneous group of clonal disorder bone
marrow (stem cell neoplasm) marked by cytopenia
and dysplasia of minimal one lineage.
• Diagnosis of MDS is mainly based on CBC, peripheral
blood smear, bone marrow aspirate and
biopsy(depends on the presence of characteristic
morfological change in the blood and marrow)
• Cytogenetic analysis and molecular biology is
important to determine prognosis, and highly variable
denpent on the subtype
• Supportive care remains but growth factor and other
specific therapeutic agent are increasing used.
Chemotherapy and stem cell transplantation may be
considered in younger patients with high-risk disease.
• Ciri khas dari penyakit multiple myeloma
(MM) adalah adanya protein M (komponen
M, protein myeloma, atau M spike)
• kadar total protein 12,3 g/dl (N=6-8,5 g/dl),
albumin 3,64 g/dl (N=3,5-5,5), dan globulin
8,66 g/dl (2,5-4,5 g/dl).
• elektroforesis protein protein
monoclonal (fraksi gamma globulin)
Sumber: Wintrobe’s Clinical Hematology 12th edition
gambaran khas suatu lesi
myeloma tunggal berupa
gambaran lusen berbatas
tegas pada regio
interocanter. Lesi-lesi lebih
kecil tampak pada
trocanter

Sulistyo M. Agustini: Department of Clinical Pathology Medicine Faculty of Muhammadiyah Malang University 2011

Uploaded by

Copyright:

Available Formats

Sulistyo M. Agustini: Department of Clinical Pathology Medicine Faculty of Muhammadiyah Malang University 2011

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Sulistyo M. Agustini: Department of Clinical Pathology Medicine Faculty of Muhammadiyah Malang University 2011

Uploaded by

Copyright:

Available Formats

MYELODYSPLASTIC SYNDROME

Refractory anaemia Blast < 1% Blast < 5 % 50

RA with ring Blast <1 % Blast <5 % ring 50

RA with excess blasts Blast < 5 % Blast 5 – 20 % 11

RAEB in transformation Blast > 5 % Blast 20-30 % or 5

Chronic As any of the above As any of the above 11

You might also like